Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation-Reference-Cited by-同舟云学术

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Published:2017-08-31 Issue:9 Volume:130 Page:1125-1131
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Newberry Kate J.¹,Patel Keyur²,Masarova Lucia¹,Luthra Rajyalakshmi²,Manshouri Taghi¹,Jabbour Elias¹,Bose Prithviraj¹,Daver Naval¹,Cortes Jorge¹,Kantarjian Hagop¹,Verstovsek Srdan¹

Affiliation:

1. Department of Leukemia and

2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months. Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/9/1125/1405191/blood783225.pdf

Reference15 articles.

1. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I;Verstovsek;Haematologica,2015

2. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016

3. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF);Cervantes;Blood,2012

4. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I;Verstovsek;Haematologica,2013

5. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib;Patel;Blood,2015

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial;The Lancet Haematology;2024-09

3. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study;Cancer;2024-07-30

5. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02